RedSail Technologies
From Wikipedia, the free encyclopedia
RedSail Technologies, Inc. (formerly known as Smith Technologies)[1] is an American company that provides pharmacy software and services.[1][2][3]
| Company type | Private |
|---|---|
| Industry | Healthcare software, Information technology |
| Founded | 2020 |
| Headquarters | Spartanburg, South Carolina, United States |
Area served | United States (primary), broader pharmacy network reach |
| Products | PioneerRx, Axys, QS/1, PowerLine, BestRx, TransactRx, Emporos, RxMile |
| Services | Pharmacy management software, pharmacy transaction services, medical billing solutions, patient engagement tools. |
| Subsidiaries |
|
| Website | www |
History
In April 2020, Francisco Partners completed its acquisition of Smith Technologies and rebranded the business as RedSail Technologies.[4][5] Prior to the acquisition, Smith Technologies was known for providing pharmacy and public sector software solutions. Later in 2020, RedSail acquired PioneerRx.[6][7] In 2023, RedSail integrated with PointClickCare Technologies.[8] In 2024, RedSail partnered with Storbie, a New-Zealand based Pharmacy website solution.[9][10][11] The same year, RedSail secured a strategic growth investment from Leonard Green & Partners (LGP).[4] In early 2025, it acquired BestRX.[6][7] In November 2025, Redsail acquired RxMile.[12][13]
Other acquisitions includes Axys long-term care pharmacy software, PowerLine, QS/1, and TransactRx.[4]
Product and services
Controversies
Antitrust scrutiny of proposed merger
In late 2025, the United States Department of Justice conducted a review of RedSail Technologies' proposed acquisition of Micro Merchants Systems, the operator of the PrimeRx pharmacy management software platform.[7] The potential challenge arose from concerns that the deal could reduce competition in the pharmacy software market for independent pharmacies, as both companies serve many of the same customers. Representatives of RedSail and Micro Merchants Systems met with the DOJ’s Antitrust chief during the confidential merger review process. The department had not reached a final decision.[6][15]